论文部分内容阅读
目的比较基础胰岛素(甘精胰岛素)联合二肽基肽酶4(DPP-4)抑制剂(西格列汀)治疗初发2型糖尿病(T2DM)的临床疗效。方法将80例初发T2DM患者随机分为观察组与对照组,每组40例。观察组给予甘精胰岛素联合西格列汀治疗,对照组给予预混胰岛素30R注射。观察两组患者BMI、FBG、餐后2-h血糖、HbA1c及低血糖发生情况。结果治疗12周,两组FBG、餐后2-h血糖、HbA1c均较治疗前降低(P<0.05),两组HbA1c达标率比较差异无统计学意义(P>0.05);观察组低血糖发生率低于对照组(2.5%vs.12.5%)(P<0.05)。结论甘精胰岛素联合西格列汀治疗初发T2DM可有效控制血糖,减少血糖波动,低血糖事件发生率低,更为安全有效,患者依从性好。
Objective To compare the clinical efficacy of basal insulin (insulin glargine) and dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin) in the treatment of newly diagnosed type 2 diabetes mellitus (T2DM). Methods Eighty patients with newly diagnosed T2DM were randomly divided into observation group and control group, 40 cases in each group. The observation group was given glargine combined with sitagliptin, and the control group was given premixed insulin 30R injection. The BMI, FBG, postprandial 2-h blood glucose, HbA1c and hypoglycemia in both groups were observed. Results After 12 weeks of treatment, the FBG, 2-h blood glucose and HbA1c after meal in both groups were significantly lower than those before treatment (P <0.05), and there was no significant difference between the two groups in the compliance rate of HbA1c (P> 0.05) The rate was lower than that of the control group (2.5% vs. 12.5%) (P <0.05). Conclusion Glargine and sitagliptin in treatment of T2DM can effectively control blood sugar, reduce blood sugar fluctuations, low incidence of hypoglycemia, more safe and effective, patients with good compliance.